Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

British Journal of Cancer
Christina TekleGodefridus J Peters

Abstract

Conventional regimens have limited impact against non-small cell lung cancer (NSCLC). Current research is focusing on multiple pathways as potential targets, and this study investigated molecular mechanisms underlying the combination of the PKC beta inhibitor enzastaurin with the multitargeted antifolate pemetrexed in the NSCLC cells SW1573 and A549. Pharmacologic interaction was studied using the combination-index method, while cell cycle, apoptosis induction, VEGF secretion and ERK1/2 and Akt phosphorylation were studied by flow cytometry and ELISAs. Reverse transcription-PCR, western blot and activity assays were performed to assess whether enzastaurin influenced thymidylate synthase (TS) and the expression of multiple targets involved in cancer signaling and cell cycle distribution. Enzastaurin-pemetrexed combination was highly synergistic and significantly increased apoptosis. Enzastaurin reduced both phosphoCdc25C, resulting in G2/M checkpoint abrogation and apoptosis induction in pemetrexed-damaged cells, and GSK3 beta and Akt phosphorylation, which was additionally reduced by drug combination (-58% in A549). Enzastaurin also significantly reduced pemetrexed-induced upregulation of TS expression, possibly through E2F-1 r...Continue Reading

References

Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E ChuC J Allegra
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·J L TonkinsonL G Mendelsohn
Feb 22, 2000·The Journal of Biological Chemistry·P R GravesH Piwnica-Worms
Apr 14, 2000·Frontiers in Bioscience : a Journal and Virtual Library·J D Black
May 23, 2000·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·B Van TriestG J Peters
Sep 29, 2000·Pharmacology & Therapeutics·G J PetersS P Ackland
Jan 5, 2002·Expert Opinion on Investigational Drugs·P G Goekjian, M R Jirousek
Jun 27, 2002·Biochimica Et Biophysica Acta·G J PetersH M Pinedo
May 17, 2003·Bioorganic & Medicinal Chemistry Letters·Margaret M FaulMichael Mohr
Nov 1, 2003·Cancer Chemotherapy and Pharmacology·Kristan A KeyesBeverly A Teicher
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Sep 1, 2004·Cell Biochemistry and Function·Bing-zhi YuJianing Yang
Jun 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Buter, G Giaccone
Jul 30, 2005·International Journal of Cancer. Journal International Du Cancer·Madhu Sudhan ShaikMandip Singh
Dec 6, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jian-Min TangXiu-Jun Chang
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary K Schwartz, Manish A Shah
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henry L GomezAxel R Hanauske
Aug 4, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·W LiL H Jiang
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciRoy S Herbst
Sep 2, 2006·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Jaco H HoutgraafWim J van der Giessen
Jan 11, 2007·Annals of Neurology·Ghazaleh TabatabaiWolfgang Wick
Mar 3, 2007·International Journal of Cancer. Journal International Du Cancer·Robert MauritzGodefridus J Peters
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeany M Rademaker-LakhaiEmile E Voest
Nov 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aaron C SpaldingEdgar Ben-Josef
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cheng-long HuangHiromi Wada
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yun OhGerold Bepler

❮ Previous
Next ❯

Citations

Dec 18, 2013·Oncogene·R GargM G Kazanietz
Dec 4, 2009·Journal of Carcinogenesis·Leonardo FaoroRavi Salgia
Sep 13, 2011·Expert Opinion on Investigational Drugs·Elena GalvaniElisa Giovannetti
Mar 23, 2017·Critical Reviews in Oncology/hematology·T BourhillR N Johnston
Aug 26, 2010·British Journal of Cancer·A KörnerH Allgayer
Sep 19, 2009·Expert Review of Anticancer Therapy·Christian ManegoldLothar R Pilz
Aug 21, 2013·Cancer Chemotherapy and Pharmacology·Guanzhong ZhangShunchang Jiao
Jun 15, 2011·Apoptosis : an International Journal on Programmed Cell Death·Juraj BodoEric D Hsi
Mar 1, 2015·Molecular Pharmacology·Mahlet B Abera, Marcelo G Kazanietz
May 3, 2014·International Journal of Oncology·I Made Winarsa RumaMasakiyo Sakaguchi
Mar 29, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhen-yu LiGang Wu
Oct 26, 2010·Molecular Cancer Therapeutics·Chad A DumstorfJeremy R Graff
Jun 3, 2021·International Journal of Molecular Sciences·Mohammad Mojtaba SadeghiYusuf A Hannun

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
flow cytometry
FACS
xenografts
xenograft

Software Mentioned

Calcusyn
[UNK]

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis